BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

 Under a three-year deal, which builds on a 2020 agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir Biotechnology Inc. (NASDAQ:VIR) on mAbs, including VIR-2482, to prevent or treat influenza....
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...acquisition last quarter by Bayer AG (Xetra:BAYN). Werewolf announced a $72 million series B round in January.IN8bio Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...graft-versus-host reactions during stem cell transplant (No. 354). In8bio Inc....
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...stocked up on our disposables,” said Larry Lam, CSO of γδ T cell therapy company Incysus...
...SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion Capital Partners Cerevance Inc. Scynexis Inc. IN8bio Inc. Codiak...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...cells in preclinical development with partners bluebird bio Inc., Scotia Biologics Ltd. and Nipro Corp. Incysus...
...Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd., London, U.K. Immatics Biotechnologies GmbH, Tuebingen, Germany Incysus...
BioCentury | Jul 20, 2018
Company News

Kite looks to Gadeta for gamma delta T cell tech

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | Jul 19, 2018
Company News

Kite, Gadeta in gamma delta T cell deal

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 25, 2018
Financial News

Lava raises €16M for gamma delta T cell platform

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 23, 2018
Financial News

Lava raises €16M for gamma delta T cell platform

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 14, 2018
Company News

Management tracks: Complexa, Immatics

...CMO and EVP. She was CMO and SVP at Adverum Biotechnologies Inc. (NASDAQ:ADVM). Immunotherapy company Incysus...
Items per page:
1 - 10 of 16
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

 Under a three-year deal, which builds on a 2020 agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir Biotechnology Inc. (NASDAQ:VIR) on mAbs, including VIR-2482, to prevent or treat influenza....
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...acquisition last quarter by Bayer AG (Xetra:BAYN). Werewolf announced a $72 million series B round in January.IN8bio Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...graft-versus-host reactions during stem cell transplant (No. 354). In8bio Inc....
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...stocked up on our disposables,” said Larry Lam, CSO of γδ T cell therapy company Incysus...
...SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion Capital Partners Cerevance Inc. Scynexis Inc. IN8bio Inc. Codiak...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...cells in preclinical development with partners bluebird bio Inc., Scotia Biologics Ltd. and Nipro Corp. Incysus...
...Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd., London, U.K. Immatics Biotechnologies GmbH, Tuebingen, Germany Incysus...
BioCentury | Jul 20, 2018
Company News

Kite looks to Gadeta for gamma delta T cell tech

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | Jul 19, 2018
Company News

Kite, Gadeta in gamma delta T cell deal

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 25, 2018
Financial News

Lava raises €16M for gamma delta T cell platform

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 23, 2018
Financial News

Lava raises €16M for gamma delta T cell platform

...Lymphocyte Activation Technologies S.A., also known as Lymphact (Evora, Portugal); Immatics Biotechnologies GmbH (Tuebingen, Germany); Incysus...
BioCentury | May 14, 2018
Company News

Management tracks: Complexa, Immatics

...CMO and EVP. She was CMO and SVP at Adverum Biotechnologies Inc. (NASDAQ:ADVM). Immunotherapy company Incysus...
Items per page:
1 - 10 of 16